The rest is here:
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
Related Post
- Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update - January 11th, 2025
- RESTEM Provides Corporate Update and Announces Key Business Objectives for 2025 - January 11th, 2025
- NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma - January 11th, 2025
- Totus Medicines Announces Successful Completion of a Phase 1 Dose-Escalation Study and Initiation of an Expansion Trial Evaluating TOS-358, a Covalent... - January 11th, 2025
- NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - January 11th, 2025
- InflammX Therapeutics Announces Option Agreement with Bausch + Lomb - January 11th, 2025
- LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - January 11th, 2025
- Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States - January 11th, 2025
- Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors - January 11th, 2025
- Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock - January 11th, 2025
- ADARx Pharmaceuticals to Present at the J.P. Morgan 43ʳᵈ Annual Healthcare Conference - January 11th, 2025
- Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in... - January 11th, 2025
- HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder - January 11th, 2025
- Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025 - January 11th, 2025
- Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs - January 11th, 2025
- Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities - January 11th, 2025
- Virbac : Declaration of the number of shares and voti - January 11th, 2025
- Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock - January 11th, 2025
- Matinas BioPharma Receives NYSE Noncompliance Notice - January 11th, 2025
- Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates - January 9th, 2025
- Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy - January 9th, 2025
- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - January 9th, 2025
- Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific... - January 9th, 2025
- Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones - January 9th, 2025
- Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - January 9th, 2025
- TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 9th, 2025
- ElevateBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 9th, 2025
- RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 9th, 2025
- Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including... - January 9th, 2025
- Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential - January 9th, 2025
- Ori Biotech Expands Team to Advance IRO Commercialization and Industry Partnerships - January 9th, 2025
- IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as... - January 9th, 2025
- Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage... - January 9th, 2025
- Biosphere Launches UV Bioreactor to Transform Industrial Fermentation - January 9th, 2025
- FYR Appoints Chris Howlett to its Board of Directors - January 9th, 2025
- Inmagene Reports Positive Topline Results of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-Life, for the Treatment of... - January 9th, 2025
- CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - January 9th, 2025
- BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco - January 9th, 2025
- Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference - January 9th, 2025
- ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease - January 7th, 2025
- Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update - January 7th, 2025
- Oncocyte Expands Market Opportunity for VitaGraft™ Kidney - January 7th, 2025
- Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases - January 7th, 2025
- ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Kura Oncology Announces Senior Executive Promotions - January 7th, 2025
- Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Umoja Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - January 7th, 2025
- Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial - January 7th, 2025
- Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA - January 7th, 2025
- Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering - January 7th, 2025
- Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide - January 7th, 2025
- Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope - January 7th, 2025
- Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe - January 7th, 2025
- Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study - January 7th, 2025
- Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights - January 7th, 2025
- Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development - January 3rd, 2025
- Atavistik Bio Announces Research Collaboration with Pfizer to Accelerate Discovery of Novel Precision Allosteric Therapeutics - January 3rd, 2025
- TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses - January 3rd, 2025
- Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office - January 3rd, 2025
- Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Lexicon Appoints Scott Coiante as Chief Financial Officer - January 3rd, 2025
- Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners - January 3rd, 2025
- SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET - January 3rd, 2025
- Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain - January 3rd, 2025
- Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular... - January 3rd, 2025
- Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference - January 3rd, 2025
- Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update - January 3rd, 2025
- Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 3rd, 2025
- Tilray Brands Moves Earnings Date to January 10, 2025, in Observance of the National Day of Mourning - January 3rd, 2025
- ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab - January 3rd, 2025
- Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering - January 1st, 2025
Recent Comments